18th week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090111678 | HIGH RESISTIVITY SILICON CARBIDE - A recrystallized silicon carbide body is provided that has a resistivity of not less than about 1 | 2009-04-30 |
20090111679 | Low creep refractory ceramic and method of making - A method is disclosed for manufacturing a zircon composition, the method comprising contacting a zircon powder with a sintering aid, wherein the sintering aid is in the form of a liquid, a sol, or a combination thereof. Also disclosed are methods for forming the zircon composition into a desired shape and for firing a composition to produce a ceramic body. The zircon composition and ceramic body produced by the described methods are also disclosed. | 2009-04-30 |
20090111680 | DIELECTRIC PORCELAIN COMPOSITION FOR USE IN ELECTRONIC DEVICES - ABSTRACT The invention intends to provide a dielectric porcelain composition for use in electronic devices which can be controlled in the temperature coefficient πf in particular in a negative direction and can shorten a sintering period while maintaining a high Qf value and a high dielectric constant. According to the invention, in conventional composition having a composition formula represented by XBa(Mg | 2009-04-30 |
20090111681 | Electrocatalysts Based on Mono/Plurimetallic Carbon Nitrides for Fuel Cells Fueled with Hydrogen - The invention describes the preparation of electrocatalysts, both anodic (aimed at the oxidation of the fuel) and cathodic (aimed at the reduction of the oxygen), based on mono- and plurimetallic carbon nitrides to be used in PEFC (Polymer electrolyte membrane fuel cells), DMFC (Direct methanol fuel cells) and H2 electrogenerators. The target of the invention is to obtain materials featuring a controlled metal composition based on carbon nitride clusters or on carbon nitride clusters supported on oxide-based ceramic materials. The preparation protocol consists of three steps. In the first the precursor is obtained through reactions of the type: a) sol-gel; b) gel-plastic; c) coagulation-flocculation-precipitation. The second step consists of the thermal treatments to decompose the precursors in an inert atmosphere leading to the production of the carbon nitrides. In the last step the chemical and electro-chemical activation of the electrocatalysts is performed. Precursors are obtained through reactions leading to: a) the complexation of a “soft” transition metal with a coordination complex acting as a ligand to obtain clusters; b) | 2009-04-30 |
20090111682 | Hydroconversion Processes Employing Multi-Metallic Catalysts and Method for Making Thereof - A process for making a catalyst precursor is disclosed. In one embodiment, the process comprises co-precipitating at reaction conditions forming a precipitate or cogel: at least a promoter metal compounds selected from Group VIII, Group IIB, Group IIA, Group IVA and combinations thereof, at least one of Group VIB metal compounds, at least an organic oxygen-containing ligand L. The precursor is represented by the formula A | 2009-04-30 |
20090111683 | Hydroconversion Processes Employing Multi-Metallic Catalysts and Method for Making Thereof - A catalyst precursor composition and methods for making such catalyst precursor are disclosed. The catalyst precursor comprises at least a Promoter metal selected from Group VIII, Group IIB, Group IIA, Group IVA and combinations thereof, at least one Group VIB metal, at least one organic, oxygen-containing ligand, and a cellulose-containing material. Catalysts prepared from the sulfidation of such catalyst precursors are used in the hydroprocessing of hydrocarbon feeds. In one embodiment, the sulfidation is carried out by contacting the catalyst precursor with hydrogen and a sulfur containing compound, wherein the contacting is carried out ex-situ. Catalysts prepared from such catalyst precursors have a fouling rate of less than 8° F. (4.4° C.) per 1000 hour. | 2009-04-30 |
20090111684 | METHOD FOR ACTIVATING STRENGTHENED IRON CATALYST FOR SLURRY REACTORS - A method of activating an iron Fischer-Tropsch catalyst by introducing an inert gas into a reactor comprising a slurry of the catalyst at a first temperature, increasing the reactor temperature from the first temperature to a second temperature at a first ramp rate, wherein the second temperature is in the range of from about 150° C. to 250° C., introducing synthesis gas having a ratio of H | 2009-04-30 |
20090111685 | Hydroconversion Processes Employing Multi-Metallic Catalysts and Method for Making Thereof - A catalyst precursor composition and methods for making such catalyst precursor is disclosed. The catalyst precursor comprises at least one of a Group IIB metal compound, a Group IVA metal compound, a Group IIA metal compound, and combinations thereof, at least one Group VIB metal, at least one organic, oxygen-containing ligand, and optionally a cellulose-containing material. Catalysts prepared from the sulfidation of such catalyst precursors are used in the hydroprocessing of hydrocarbon feeds. In one embodiment, the catalyst precursor is of the formula A | 2009-04-30 |
20090111686 | Hydroconversion Processes Employing Multi-Metallic Catalysts and Method for Making Thereof - A catalyst precursor composition and methods for making such catalyst precursor are disclosed. The catalyst precursor comprises at least a metal compound selected from Group VIII, Group IIB, Group IIA, Group IVA and combinations thereof, at least one Group VIB metal, at least one organic, oxygen-containing ligand, and a cellulose-containing material. Catalysts prepared from the sulfidation of such catalyst precursors are used in the hydroprocessing of hydrocarbon feeds. In one embodiment, the sulfidation is carried out by contacting the catalyst precursor with hydrogen and a sulfur containing compound in a “slow” process with the sulfidation taking place over a few days up to two weeks, e.g., for at least over 96 hours. In another embodiment, the sulfidation is in a “quick” process with the sulfidation taking place in less than 72 hours. The catalyst prepared from the slow sulfidation process gives a 700° F.+ conversion rate of at least 25% higher than the 700° F.+ conversion rate of a catalyst prepared from a quick sulfidation process. | 2009-04-30 |
20090111687 | CATALYST DESIGN AND PREPARATION PROCESS FOR STEAM-REFORMING CATALYSTS - The invention relates to a catalyst with large surface area structure, in particular for steam-reforming catalysts, which is characterised in that the large surface area structure is formed of a large number of round or parallel penetrating holes of polygonal cross-section, wherein the catalyst carrier is prepared in the injection moulding process, coated with a washcoat and then impregnated with the active component. The catalyst carrier includes at least one sinterable material and has a lateral pressure resistance of at least 700 N. The invention further relates to a process for the preparation of such catalysts and the use thereof in a reactor. | 2009-04-30 |
20090111688 | Exhaust Gas Purifying Catalyst and Production Method Thereof - An object is to maintain an effect of enhancing activity of noble metal particles by transition metal without increasing production cost and an environmental load. | 2009-04-30 |
20090111689 | COMPOSITION AND PROCESS FOR MAKING THE COMPOSITION - An aggregate composition and process for making the aggregate composition. The aggregate composition includes an insoluble rare earth-containing compound and a polymer binder. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from cerium carbonate or a cerium salt. In a specific embodiment, the aggregate composition consists essentially of one or more cerium oxides, the polymer binder and optionally a flow aid. A process for making the composition includes mixing the insoluble rare earth-containing compound with a polymer binder to form a mixture, and subjecting the mixture to mechanical, chemical and/or thermal treatment to adhere the rare earth compound to the polymer binder. The aggregate composition can be used in a variety of fluid treatment applications to remove one or more chemical and biological contaminants in a fluid. | 2009-04-30 |
20090111690 | Sorbent comprising activated carbon, process for making same and use thereof - A sorbent body adapted for abating toxic elements from a fluid stream, such as a carbon combustion flue gas stream or a syngas stream produced in coal gasification process, and process for making such sorbent. The sorbent body comprises an activated carbon matrix defining a plurality of pores, sulfur and an additive adapted for promoting the abatement of toxic elements from the fluid stream. At least one of the additive is formed into the sorbent body by in-situ forming such as in-situ extrusion. The sorbent is useful for abatement of, e.g., arsenic, cadmium, mercury and selenium from gas streams. | 2009-04-30 |
20090111691 | Fungicides and Bioregulatory Mixtures - Fungicidal and bioregulatory mixtures, comprising
| 2009-04-30 |
20090111692 | 3-(Pyridin-2-Yl)-[1,2,4]-Triazines as Fungicides - The invention relates to 3-(pyridin-2-yl)-[1,2,4]-triazines of formula (I) and their use in the control of parasitic fungi and to herbicides that contain said compounds as an effective ingredient thereof. In formula (I), R | 2009-04-30 |
20090111693 | Phytotoxicity Controlling Agent for Upland Farming and Phytotoxicity Controlling Method Using the Same - It is intended to provide a phytotoxicity controlling agent usable as a herbicide for upland farming, which exerts a sufficient herbicidal effect on weeds growing together with upland crops, for example, wheat, rye, barley, oat, corn, sorghum, cotton, soybean, adzuki bean, oilseed rape, beet, upland rice and so on but causes no phytotoxic phenomenon (for example, growth inhibition, growth suppression, tiller inhibition or yellowing) in cultivated plants, comprising a nuclear-substituted benzoic acid represented by the following general formula: | 2009-04-30 |
20090111694 | Methods and Compositions for Treating Pollution - This invention relates to compositions and methods for improving water quality by enhancing natural bacterial processes and altering environmental conditions in situ. This is achieved by the manufacture and use of granules or tablets composed of the inventive formulations. | 2009-04-30 |
20090111695 | AROMATIC SOLVENT FREE HERBICIDAL FORMULATIONS OF FLUROXYPYR MEPTYL ESTER WITH C4-C8 ESTERS OF TRICLOPYR, 2,4-D OR MCPA - This invention relates to formulations of fluoroxypyr meptyl ester with C | 2009-04-30 |
20090111696 | Pyridazinone Compound and Use Thereof as herbicides - A pyridazinone compound represented by the formula (I) | 2009-04-30 |
20090111697 | PROPIONIC ACID AS AN HERBICIDE - The present invention discloses that, propionic acid or salt thereof, is an effective pre-emergent and post-emergent herbicide. Propionic acid biodegrades first to acetic and formic acids and then to carbon dioxide and water thus posing not threat the environment. Propionic acid is less caustic and corrosive than formic acid, and with proper formulation and the use of respiratory protection, it poses no threat to the applicator. Propionic acid is demonstrated in this invention to control both monocotyledonous and dicotyledonous plants. | 2009-04-30 |
20090111698 | Enhancement of Plant Growth - Treatment with N-(2-phenylethyl)succinamic acid or its salts protects against inhibition of growth by a neonicotinoid compound applied as a seed treatment or applied directly on or near the root zone of the seedling. | 2009-04-30 |
20090111699 | Weakly Basic Hindered Amines Having Carbonate Skeletons, Synthetic Resin Compositions, And Coating Compositions - Hindered amines represented by the general formula (I): (wherein R is an alkyl or hydroxyalkyl group having 1 to 30 carbon atoms or alkenyl having 2 to 30 carbon atoms; n is an integer of 1 to 4; when n is 1, R | 2009-04-30 |
20090111700 | Superconducting Strip Having Metal Coating Layer And Method Of Manufacturing The Same - Disclosed herein is a superconducting strip having a metal coating layer and a method of manufacturing the superconducting strip. The method of manufacturing the superconducting strip includes: washing a superconducting thin film, a stabilizing substrate and an anti-bonding substrate with alcohol; forming a metal coating layer on each of the superconducting thin film and stabilizing substrate; adhering the superconducting thin film and stabilizing substrate to each other such that the metal coating layer formed on the superconducting thin film faces the metal coating layer formed on the stabilizing substrate; disposing the anti-bonding substrate on an outside of the stabilizing substrate and then winding the anti-bonding substrate such that the anti-bonding substrate and the stabilizing substrate are closely adhered to each other by winding the anti-bonding substrate around a bobbin under a predetermined tension; and heat-treating the superconducting thin film and stabilizing substrate such that they are bonded to each other by the metal coating layer disposed therebetween. | 2009-04-30 |
20090111701 | METHOD OF PREPARING A SUBSTRATE WITH A COMPOSITION INCLUDING AN ORGANOBORANE INITIATOR - A method of preparing a substrate with a composition comprising (i) an organoborane initiator and (ii) a radical curable component disposed thereon includes the step of depositing the composition onto the substrate wherein at least one of (i) the organoborane initiator and (ii) the radical curable component is deposited onto the substrate in the form of a gradient pattern. An article comprises the substrate and the gradient pattern formed on the substrate. The gradient pattern is formed from a developed composition comprising the reaction product of (i) the organoborane initiator and (ii) the radical curable component. By forming the gradient pattern on the substrate, combinatorial and high-throughput methods of generating and testing the developed composition are possible, which enable characterization of the developed composition for various physical and chemical properties. | 2009-04-30 |
20090111702 | Methods of determining allergen response using microarray immunoassay techniques - The present invention is directed to materials and methods that may be used in diagnosing and/or characterizing allergies. More specifically, the specification describes methods and compositions for making and using a plurality of peptides having allergen epitopes that may be used in immunoassays e.g., microarray-based immunoassays to predict the severity of an allergic response. | 2009-04-30 |
20090111703 | SUBSTRATE INDEPENDENT COPOLYMERS FOR BIOFUNCTIONALIZATION - The present invention provides crosslinked epoxy-functional copolymer films and microarrays built from the crosslinked epoxy-functional copolymer films. Microarrays incorporating the copolymers include a substrate on which a film of the crosslinked epoxy-functional copolymer is disposed and target molecules bound to the copolymer film. The crosslinked polymer films are well-suited for use as scaffolds for target molecules in microarrays because they provide a high density of binding sites for the target molecules, are mechanically stable, and may be coated onto a wide range of substrates. | 2009-04-30 |
20090111704 | PANEL FOR THE DETECTION AND DIFFERENTIATION OF RENAL CORTICAL NEOPLASMS - The present invention provides a novel, highly sensitive and specific probe panel which detects the type of renal cortical neoplasm present in a biopsy sample. As such, the invention permits diagnosis of the predominant subtypes of renal cortical neoplasms without the use of invasive methods. The present invention further provides a molecular cytogenetic method for detecting and analyzing the type of renal cortical neoplasm present in a renal biopsy sample. | 2009-04-30 |
20090111705 | SELECTION OF DNA ADAPTOR ORIENTATION BY HYBRID CAPTURE - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another by employing selective capture of defined molecules. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 2009-04-30 |
20090111706 | SELECTION OF DNA ADAPTOR ORIENTATION BY AMPLIFICATION - Aspects described and claimed herein provide methods to insert multiple DNA adaptors into a population of circular target DNAs at defined positions and orientations with respect to one another by employing amplification procedures. The resulting multi-adaptor constructs are then used in massively-parallel nucleic acid sequencing techniques. | 2009-04-30 |
20090111707 | MARKERS FOR THE PREDICTION OF OUTCOME OF ANTHRACYCLINE TREATMENT - The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods. | 2009-04-30 |
20090111708 | POLYNUCLEOTIDES ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AND METHODS FOR EVALUATING PATIENT RISK - The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors. | 2009-04-30 |
20090111709 | Affinity Measurements Using Frameless Multiplexed Microarrays - The present invention relates to novel methods of the quantitative detection of molecules in an array. In particular, the present invention relates to methods for molecular detection assays performed on solid surfaces. The present invention provides improved methods for the high throughput analysis of molecular interactions and quantitative detection. In another aspect, the invention relates to a method of measuring protein interactions on a solid surface that is useful for the determination of equilibrium binding and rate constants. In yet another aspect, the invention relates to predicting a molecules utility in a detection assay. | 2009-04-30 |
20090111710 | CELLULAR SIGNALING PATHWAY BASED ASSAYS, REAGENTS AND KITS - The present invention is directed to an assay system, PAM (Pathway Assay Matrix) for screening drug to determine whether they are effective for treating or preventing a disease or disorder. This assay system takes into account that many diseases involve complex pathways, and measures the effect of a particular drug on the multiple nodes within the disease pathway of a particular disease or disorder. | 2009-04-30 |
20090111711 | DEVICE AND METHOD FOR HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION CONDITIONS IN A VAPOR DIFFUSION ENVIRONMENT - A high-density high-throughput microplate and methods for simultaneously screening a plurality of protein crystallization solutions and for producing diffraction quality protein crystals in a vapor-diffusion environment are disclosed. The microplate has defined side-by-side paired chambers of equal size, wherein the side-by-side paired chambers have a maximum volume of about 8 μl, and wherein the paired chambers have a vapor channel, therein providing vapor exchange between the side-by-side paired chambers. The microplate further includes a membrane to seal the surface of the microplate. The microplate is adapted to receive a crystallization solution in one of the side-by-side paired chambers and a protein solution in the other of the side-by-side paired chambers, wherein the protein solution and the crystallization solution interact via a vapor diffusion process, which enables the formation of protein crystals within the chamber that contains the protein solution. | 2009-04-30 |
20090111712 | DETECTION AND QUANTIFICATION OF BIOMOLECULES USING MASS SPECTROMETRY - The present invention is directed in part to a method for detecting a target nucleic acid using detector oligonucleotides detectable by mass spectrometry. This method takes advantage of the 5′ to 3′ nuclease activity of a nucleic acid polymerase to cleave annealed oligonucleotide probes from hybridized duplexes and releases labels for detection by mass spectrometry. This process is easily incorporated into a polymerase chain reaction (PCR) amplification assay. The method also includes embodiments directed to quantitative analysis of target nucleic acids. | 2009-04-30 |
20090111713 | Method for biomolecule immobilization - The present invention relates to a method for biomolecule immobilization, comprising: providing a substrate; forming a surface modification layer of carboxy groups on one surface of the substrate, wherein the process for forming the surface modification layer comprises plasma surface modification; and providing pluralities of biomolecules and bonding the biomolecules with the surface modification layer. Accordingly, the method for biomolecule immobilization of the present invention can reduce manufacturing time and enhance the stability of manufacture. In addition, the method can be employed in a biosensor to efficiently enhance sensitivity of the biosensor. | 2009-04-30 |
20090111714 | DISPERSE NON-POLYALPHAOLEFIN DRAG REDUCING POLYMERS - A drag reducing composition comprising at least one non-polyalphaolefin polymer having an average particle size in the range of from about 5 to about 800 micrometers. The non-polyalphaolefin polymer can initially be formed via emulsion polymerization. The initial polymer particles can then be at least partially consolidated and then reduced in size and suspended in a carrier fluid. The resulting drag reducing composition can be added to a hydrocarbon-containing fluid to decrease the pressure drop associated with the turbulent flow of the hydrocarbon-containing fluid through a conduit. | 2009-04-30 |
20090111715 | Method for remediating flow-restricting hydrate deposits in production systems - A method to remove hydrate plugs in a production system by passing a non-hydrate-forming or a hydrate-forming gas, which forms hydrates at a higher pressure than the existing hydrate, through the flow-restricting hydrate. | 2009-04-30 |
20090111716 | ADDITION OF ZWITTERIONIC SURFACTANT TO WATER SOLUBLE POLYMER TO INCREASE THE STABILITY OF THE POLYMERS IN AQUEOUS SOLUTIONS CONTAINING SALT AND/OR SURFACTANTS - An aqueous fluid composition useful for the recovery of hydrocarbons from a subterranean formation, including a mixture of water, a water soluble polymer, an inorganic salt and at least one zwitterionic surfactant and methods of using same. | 2009-04-30 |
20090111717 | ENHANCED OIL RECOVERY SURFACTANT FORMULATION AND METHOD OF MAKING THE SAME - The present invention is directed to an enhanced oil recovery formulation which comprises:
| 2009-04-30 |
20090111718 | Control of Fines Migration In Well Treatments - A treatment fluid that can be used for treating a subterranean formation penetrated by a wellbore is prepared from a primary treatment fluid component and an emulsion component mixed with the primary treatment fluid component. The emulsion component has an oil phase and an aqueous phase. The emulsion component comprising a source of insoluble silica particles and a source of calcium hydroxide, wherein the source of calcium hydroxide is present in the oil phase, and the source of insoluble silica particles are contained in the aqueous phase. The method is carried out by contacting at least a portion of the formation with the treatment fluid. | 2009-04-30 |
20090111719 | Additive mixtures - An additive mixture containing the components (A), (B) and optionally (C), wherein component (A) is at least one compound of the formula (I) | 2009-04-30 |
20090111720 | LUBRICATING OIL COMPOSITIONS COMPRISING A BIODIESEL FUEL AND AN ANTIOXIDANT - This invention encompasses a lubricating oil composition contaminated with at least about 0.3 wt % of a biodiesel fuel or a decomposition product thereof, based on the total weight of the lubricating oil composition, comprising:
| 2009-04-30 |
20090111721 | LUBRICATING OIL COMPOSITIONS COMPRISING A BIODIESEL FUEL AND A DETERGENT - This invention encompasses lubricating oil compositions comprising a base oil, a biodiesel fuel and a detergent. The detergent can be a metal phenate detergent such as alkaline metal phenates. The lubricating oil compositions can further comprise at least one antiwear agent such as zinc dialkyl dithiophosphate compounds. Methods of making and using the lubricating oil compositions are also described. | 2009-04-30 |
20090111722 | ENGINE WEAR PROTECTION IN ENGINES OPERATED USING ETHANOL-BASED FUEL - Lubricant formulations and methods for producing lubricant formulations are described that provide improved wear protection in engines operated using ethanol-based fuels. The improved wear protection may be provided by an increased amount of overbased calcium detergent present in the formulation. | 2009-04-30 |
20090111723 | Multifunctional hydrocarbon oil composition - A multifunctional, high-performance hydrocarbon composition is demanded. Concretely, a metalworking oil composition having high workability even under a severer lubricating condition while resisting to high productivity, and further capable of suppressing deterioration of working environments or degradation of quality of a product without rise of lubricant cost, a metalworking oil composition for minimal quantitative lubrication system, which is excellent in characteristics as a water-insoluble lubricant for nonferrous metalworking and also in characteristics as a lubricant for cutting/grinding by minimal quantitative lubrication method, and can attain improvement in working efficiency and a further extended tool life, an electric discharge machining oil improved in working environments such as odor or skin roughness and further improved in processing rate, particularly processing rate in high-level finish, a rust preventing oil composition improved in resin compatibility, and a detergent excellent in adaptability with organic material are demanded. | 2009-04-30 |
20090111724 | Natural Cleaning Compositions - A cleaning composition with a limited number of natural ingredients contains alkyl polyglucoside, solvent, acetic acid and water. The cleaning composition optionally contains dyes, glycerol, builders, fatty acids, polymers, fragrances, colorants, anti-foaming agents and preservatives. The cleaning composition can be used to clean hard surfaces and cleans as well or better than commercial compositions containing synthetically derived cleaning agents. | 2009-04-30 |
20090111725 | Exfoliating scrub bar - An exfoliating scrub bar for various parts of the body is made from natural ingredients that exfoliate the skin gently and effectively. The scrub bar comprises powdered or crushed nuts; powdered or crushed oats; and glycerin. The combination of ingredients allows a person to gently exfoliate different parts of the body depending on the location and/or skin sensitivity. The scrub bar provides the user with an effective tool for exfoliation that allows for the removal of dead skin cells. | 2009-04-30 |
20090111726 | Compounds for Photoresist Stripping - A composition for removing undesired matter from a substrate, the composition comprising hydroxylamine or a hydroxylamine derivative, a quaternary ammonium compound and at least one polar organic solvent. The composition is capable of removing photoresist from wafer level packaging and solder bumping applications. | 2009-04-30 |
20090111727 | SOLID FABRIC SOFTENING COMPOSITION - A solid fabric softening composition which is suitable for adding to a heated tumble dryer along with fabric articles comprises a cationic softening agent, a sublimable carrier substance, silicone wax and a fragrance. The composition disintegrates to provide softening with good fragrance substantivity. | 2009-04-30 |
20090111728 | Fabric Softening Compositions Having Improved Stability Upon Storage - The present invention relates to fabric softening compositions providing improved stability upon storage as well as improved resistance to shear. | 2009-04-30 |
20090111729 | Infused Sealant System - An infused sealant system for providing a sealant infused with a crystal powder and/or essential oil. The infused sealant system generally includes a composition comprised of a sealant infused with a crystal powder. The composition preferably includes one or more essential oils infused within the sealant. The composition is applied as a coating or an adhesive to an object in a liquid state and allowed to dry thereby sealing the crystal powder and/or essential oils within the sealant. | 2009-04-30 |
20090111730 | Polypeptide protracting tags - Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere. | 2009-04-30 |
20090111731 | NOVEL TOPICAL APPLICATION AGENTS AGAINST MIMIC AND AGE-RELATED WRINKLES - The compounds of formula (I) | 2009-04-30 |
20090111732 | Gelling Hydrophobic Injectable Polymer Compositions - Biodegradable carriers synthesized from ricinoleic acid oligoesters and aliphatic molecules having at least one carboxylic acid and at least one hydroxy or carboxylic acid group that are liquids or pastes at temperatures below 37° C. and methods of making and using thereof are described herein. The polymers described herein significantly increase their viscosity upon immersion in aqueous medium. These polymers can be used as hydrophobic biomedical sealants, temporary barriers to prevent adhesions, such as organ to organ adhesion, cell supports, carriers for drug delivery, and coatings on implantable medical devices, such as stents. The polymers made from ricinoleic acid oligoesters are less viscous and easier to inject compared to polymers of similar composition and molecular weight prepared from ricinoleic acid monomers, possess a higher molecular weight, retain an incorporated drug for longer periods, and degrade into soft degradation products at a slower rate compared with polymers synthesized from ricinoleic acid monomers. Pharmaceutically active agents can be incorporated into the liquid or pastes without the use of organic solvents. | 2009-04-30 |
20090111733 | PAR-4 RELATED METHODS AND COMPOSITIONS - Provided herein are methods and compositions for treating or preventing mood disorders and certain other mental disorders. Methods may comprise increasing PAR-4 levels or activity and/or the interaction between PAR-4 and the dopamine (D2) receptor | 2009-04-30 |
20090111734 | COMPOSITIONS AND METHODS FOR PROMOTING HEMOSTASIS AND OTHER PHYSIOLOGICAL ACTIVITIES - Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaiminate a site upon removal of previously applied compositions that provided a protective coating, and to inhibit the movement of bodily substances other than blood. The compositions are also useful in isolating tissue, removing tissue, preserving tissue (for, e.g., subsequent transplantation or reattachment), and as bulking, stabilizing or hydrating agents. Medical devices that include the compositions (e.g., a stent or catheter), bandages or other wound dressings, sutures, and kits that include the compositions are also described. | 2009-04-30 |
20090111735 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents - Novel compositions and formulations are disclosed that have use to mitigate or prevent physiologically deleterious side-effects and/or modulate the intracellular balance of oxidized and reduced thioredoxin (Trx) in patients with cancer who are receiving treatment with one or more chemotherapeutic agents. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium (mesna). In addition, methods of administration and kits comprising these novel mesna heteroconjugates are disclosed. | 2009-04-30 |
20090111736 | Orally-Absorbed Solid Dose Formulation for Vancomycin - An orally bioavailable pharmaceutical composition comprises at least 40% (w/w) vancomycin; a permeation enhancer component comprising 0.1 to 10.0% (w/w) of a polyoxyethylene sorbitan fatty acid ester; and a particulate carrier onto which the permeation enhancer component is adsorbed. | 2009-04-30 |
20090111737 | Novel antibacterial agents - This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has
| 2009-04-30 |
20090111738 | FIBRONECTIN POLYPEPTIDES AND METHODS OF USE - Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin). | 2009-04-30 |
20090111739 | SUGAR CHAIN ADDED GLP-1 PEPTIDE - The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog. | 2009-04-30 |
20090111740 | USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF PATIENTS SUFFERING FROM COGNITIVE DISORDERS - The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of Aβ in the patient's blood. | 2009-04-30 |
20090111741 | METHOD FOR TREATING AND/OR PREVENTING DRUG SEEKING BEHAVIOR - A dynorphin-A analog can be used for treatment, inhibition, and/or prevention of cocaine seeking behavior, and or the drug seeking behavior for a cocaine derivative or other structurally related substance. The dynorphin-A analog can be a cyclic dynorphin-A analog having sufficient systemic stability that crosses the blood-brain barrier so as to be active in the brain at kappa-opioid receptors (KOR) as an antagonist. Such activity at a KOR as an antagonist can be useful for cocaine management and reducing the desire, such as stress-related desires, for use of cocaine, crack, or the like. The KOR antagonist can be [N-benzylTyr | 2009-04-30 |
20090111742 | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes - A method for treating type 2 diabetes and metabolic syndrome comprising administering an effective amount of fibroblast growth factor 21 in combination with a thiazolidinedione. | 2009-04-30 |
20090111743 | Cysteine-branched heparin-binding growth factor analogs - The present invention provides a heparin binding growth factor analog of any of formula I-VIII and methods and uses thereof. | 2009-04-30 |
20090111744 | Human Growth Gene and Short Stature Gene Region - Subject of the present invention is an isolated human nucleic acid molecule encoding polypeptides containing a homeobox domain of sixty amino acids having the amino acid sequence of SEQ ID NO: 1 and having regulating activity on human growth. Three novel genes residing within the about 500 kb short stature critical region on the X and Y chromosome were identified. At least one of these genes is responsible for the short stature phenotype. The cDNA corresponding to this gene may be used in diagnostic tools, and to further characterize the molecular basis for the short stature-phenotype. In addition, the identification of the gene product of the gene provides new means and methods for the development of superior therapies for short stature. | 2009-04-30 |
20090111745 | Plad Domain Peptides With Increased Serum Half Life Due To Conjugation To Domain Antibodies - Drug fusions and conjugates that contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent. | 2009-04-30 |
20090111746 | MODULATING TOLL-LIKE RECEPTOR ACTIVITY - This description provides methods and materials related to modulating Toll-like receptor activity. For example, methods and materials for increasing or decreasing the responsiveness of a TLR4 polypeptide are provided. | 2009-04-30 |
20090111747 | Anti-Diabetic or Anti-Hypertensive Dietary Supplement - An anti-diabetic or anti-hypertensive fish protein hydrolysate is provided, in which the fish is of the genus | 2009-04-30 |
20090111748 | FIBROBLAST GROWTH FACTOR-2 PROMOTES NEUROGENESIS AND NEUROPROTECTION AND PROLONGS SURVIVAL IN HUNTINGTON'S DISEASE - This invention pertains to the discovery that fibroblast growth factor 2 (FGF2) stimulates neurogenesis, induces migration of newborn cells into the striatum and cortex, is neuroprotective, and significantly extends the lifespan mammals suffering from neurodegenerative conditions (e.g., Huntington's disease, Parkinson's disease, etc.). In certain embodiments this invention provides a method of promoting neurogenesis, neuroprotection and/or survival in a mammal having a neurodegenerative disease by upregulating expression or availability of endogenous fibroblast growth factor 2 (FGF2) in said mammal; and/or administering FGF2 or an FGF2 mutein to the mammal in an amount sufficient to promote neurogenesis, neuroprotection and/or survival of the mammal. | 2009-04-30 |
20090111749 | Delivery of Active Agents - A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site. | 2009-04-30 |
20090111750 | KERATIN DERIVATIVES AND METHODS OF MAKING THE SAME - Soluble keratin derivatives are disclosed. The soluble keratin derivatives may include a soluble keratin protein having at least one substituted chemical group at a lysine group, terminal amine group and/or hydroxyl amino acid group of a soluble keratin protein. Soluble keratin derivatives may be formed by succinylation or quaternisation, or by reaction with fatty acid derivatives. The soluble keratin derivatives may be used in personal care formulations, and may also comprise mixtures of several different soluble keratin derivatives. | 2009-04-30 |
20090111751 | Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation - The invention relates to a method for removing a protein inhibitor from a liquid pharmaceutical preparation, said method comprising the steps of: (a) providing a sealed container comprising an initial liquid pharmaceutical preparation comprising (i) a protein belonging to the group of serine proteases/Vitamin K-dependent proteins and (ii) a non-metallic inhibitor for said protein; (b) contacting said pharmaceutical preparation with a solid phase polymeric material capable of retaining at least a substantial portion of said inhibitor; and (c) separating said liquid pharmaceutical preparation from said solid phase polymeric material so as to obtain a resulting liquid pharmaceutical preparation having a reduced concentration of said inhibitor compared to the initial liquid pharmaceutical preparation. | 2009-04-30 |
20090111752 | Stable Formulation of Modified GLP-1 - Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof. | 2009-04-30 |
20090111753 | Nogo-A Polypeptide Fragments, Variant Nogo Receptor-1 Polypeptides, and Uses Thereof - Nogo, MAG, and OMgp are myelin-derived proteins that bind to a neuronal Nogo-66 Receptor (NgR) to limit axonal regeneration after CNS injury. Nogo-A protein may play the most prominent role in vivo, perhaps because its action is mediated both by NgR and by other receptors. Here, we extend our previous analysis of Nogo-A and NgR functional domains. In addition to a NgR-dependent Nogo-66 inhibitory domain and a NgR-independent Amino-Nogo-A specific domain, we identify a third Nogo-A specific domain that binds to NgR with nanomolar affinity. This third domain of 19 amino acids (aa) does not alter cell spreading or axonal outgrowth. Ala-scanning mutagenesis of surface residues in NgR partially distinguishes ligand binding sites for the two Nogo domains and for MAG, OMgp and Lingo-1. Fusion of the two NgR-binding Nogo-A domains creates a ligand with ten-fold enhanced affinity for NgR and converts a NgR antagonist peptide to an agonist. Thus, inhibition of axonal regeneration by NgR occurs after binding a subnanomolar bipartite Nogo-A ligand at a site partly overlapping with that for MAG and OMgp. | 2009-04-30 |
20090111754 | Selective Inhibitors of Nuclear Factor KappaB Activation and Uses Thereof - The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-κB activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H | 2009-04-30 |
20090111755 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES - The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders. | 2009-04-30 |
20090111756 | Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus - Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2009-04-30 |
20090111757 | HCV PROTEASE INHIBITORS - Compounds of formula (I): | 2009-04-30 |
20090111758 | USE OF THERAPEUTICALLY USEFUL PEPTIDES - The invention relates to preventing and treating endothelial dysfunction by using biologically active peptides and products containing them. In particular, the tripeptides Ile-Pro-Pro (IPP), Val-Pro-Pro (VPP) or mixtures, concentrates or other products containing them are used. A specific aspect of the present invention is to enhance the elasticity of blood vessels by using said biologically active peptides. | 2009-04-30 |
20090111759 | Synergistic Combination of Glutamate-and Gaba-Gated Chloride Agonist Pesticide and at Least One Vitamin E, Niacin, or Derivatives Thereof - Presented are pesticidal compositions comprising at least one pesticide selected among Glutamate- or GABA-gated chloride channel agonist pesticides and at least one synergist which is selected among Vitamin E, Niacin and derivatives thereof. The combinations of these compounds show a synergistic effect allowing a composition to be prepared comprising a lesser amount of pesticide, while still controlling the harmful pests. | 2009-04-30 |
20090111760 | MACROLONE COMPOUNDS - A compound of formula (I) | 2009-04-30 |
20090111761 | Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions - The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair. The present invention further relates to the formulation and delivery of prostaglandin analogs to reduce intraocular pressure. | 2009-04-30 |
20090111762 | METHOD OF DIAGNOSING AND TREATING CANCER USING B-CATENIN SPLICE VARIANTS - The invention relates to method of diagnosing and treating cancer, in particular β-catenin related cancers. The invention further relates to methods of identifying CTNNB1 related cancer CTNNB1 therapeutics. | 2009-04-30 |
20090111763 | LOADABLE POLYMERIC PARTICLES FOR BONE AUGMENTATION AND METHODS OF PREPARING AND USING THE SAME - Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided for placement within defects in bone within the body of a mammal to augment structural support and facilitate osteogenesis without causing adverse reactions therein. The hydrogel core may further be used as a delivery vehicle for therapeutic agents to treat or retard pathologic processes within the bone defect during healing. | 2009-04-30 |
20090111764 | Mitochondrial selection - Systems, methods, compositions and apparatus relating to genome, chromosome, and mitochondria selection are disclosed. | 2009-04-30 |
20090111765 | COMPOSITIONS AND METHODS FOR IMMUNOSTIMULATORY RNA OLIGONUCLEOTIDES - The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes. | 2009-04-30 |
20090111766 | RAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES - Disclosed are recombinant adeno-associated viral (rAAV) vector compositions that are expressed in selected mammalian cells, such as pancreatic islets cells, and that encode one or more mammalian serpin or cytokine polypeptides having therapeutic efficacy in the amelioration, treatment and/or prevention of interleukin deficiencies, such as for example diabetes, and related diseases of the pancreas. Also disclosed are methods and compositions for preventing diabetes in a mammal, reducing the rate of disease progression, and ameliorating the symptoms of diabetes in humans at risk for developing such conditions. | 2009-04-30 |
20090111767 | MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION - The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions. | 2009-04-30 |
20090111768 | Regulators of protein misfolding and neuroprotection and methods of use - Polynucleotide molecules and the proteins encoded by the molecules, diagnostic and treatment methods for neurological disorders characterized by protein aggregation are provided. Genes are described herein that affect the misfolding of, and subsequent aggregation of, aggregation-prone proteins such as alpha-synuclein and have implications for the diagnosis and treatment of neurological diseases related to protein aggregation such as Parkinson's disease. Knockdown of expression of the genes described herein using RNAi results in alpha-synuclein protein aggregation in a | 2009-04-30 |
20090111769 | Antithrombotic Compound - The present invention relates compounds of the formula I: oligosaccharide-spacer-GpIIb/IIIa antagonist I, wherein the oligosaccharide is a negatively charged pentasaccharide residue of the structure (I), the charge being compensated by positively charged counterions; the spacer is an essentially pharmacologically inactive linking residue of a length of 15-50 atoms; the GpIIb/IIIa antagonist is a residue derived from tirofiban or an analogue thereof; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. | 2009-04-30 |
20090111770 | Pharmaceutical Composition Free From Dexpanthenol, Calcium Ions, and Phosphate and Use of Calcium Chelating Agent and Ophthalmologically Compatible Viscosity Regulator - The invention relates to a pharmaceutical composition free from dexpanthenol, calcium ions and phosphate, comprising at least one calcium chelating agent and at least one opthalmologically compatible viscosity regulator and optionally one or more pharmaceutical excipients. The invention further relates to the use of a calcium chelating agent and an opthalmologically compatible viscosity regulator for the production of a phosphate-free pharmaceutical composition for the treatment and/or prevention of epithelial defects. | 2009-04-30 |
20090111771 | INHIBITION OF CATHEPSIN K ACTIVITY AND THE TREATMENT AND PREVENTION OF DISEASE - The present invention provides a candidate compound that is suitable for use in methods of treating animals (preferably mammals) and in the preparation of a medicament, wherein the candidate compound down regulates Cathepsin K activity. | 2009-04-30 |
20090111772 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors. | 2009-04-30 |
20090111773 | Compositions and methods of using lamellar bodies for modifying linear biological macromolecules - Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions, such as otitis media, cystic fibrosis, bronchitis, sinusitis and nasal congestion. Methods of treating these diseases and conditions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed. | 2009-04-30 |
20090111774 | PMEA LIPID CONJUGATES - The present invention relates to PMEA lipid conjugates and to methods of using the conjugates to treat diseases caused by viruses such as herpes, cytomegalovirus, varicella, paramyxovirus, polyoma virus, and human papillomavirus. Methods for making the PMEA lipid conjugates are also provided. | 2009-04-30 |
20090111775 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo - Novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on a dendrimeric scaffold having a tri-functional core. The tri-functional core is a phosphorodiamidate or phosphoramide moiety. | 2009-04-30 |
20090111776 | Novel tetracycline derivatives as antibacterial agents - In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. | 2009-04-30 |
20090111777 | Jelly Composition - It is intended to provide a composition having at least one effect among the following effects; a plurality of medicinal ingredients can be taken as one preparation and the convenience for patients is excellent; the drug compliance is excellent; the amount of jelly composition to be taken at a time is small; the release of an active ingredient in the digestive tract is excellent; the absorption of an active ingredient to the body is excellent; the storage stability of an active ingredient is excellent; the dispersibility of an active ingredient in the composition is excellent; the storage stability of the composition is excellent; the syneresis of the composition is less, it has an appropriate jelly strength to a degree that does not disintegrate during carrying and before taking and easily disintegrates after taking; the handleability during preparation of the composition is excellent; the portability of the composition is excellent; the feeling of taking the composition is excellent; it has an effect on reducing side effects; and the like. The jelly composition contains a polyvalent unsaturated fatty acid, a second medicinal ingredient, an emulsifying agent and a gelling agent. | 2009-04-30 |